Treatment patterns and health care resource utilization in a 1-year observational cohort study of outpatients with schizophrenia at risk of nonadherence treated with long-acting injectable antipsychotics

Patient Preference and Adherence

Volumn 5, Issue , 2011, Pages 601-610

  Bernardo, Miguel ^a   San, Luis ^b   Olivares, José M ^c   Dilla, Tatiana ^d   Polavieja, Pepa ^d   Gilaberte, Inmaculada ^d   Álvarez, María ^d   Ciudad, Antonio ^d  

^a UNIVERSITY OF BARCELONA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^c Complejo Hospitalario de Vigo ^*  (Spain)

^d ELI LILLY AND COMPANY   (Spain)

Author keywords

Depot preparations; Health care costs; Medication adherence

Indexed keywords

ARIPIPRAZOLE; FLUPHENAZINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZUCLOPENTHIXOL;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG COST; DRUG EFFICACY; DRUG USE; FEMALE; FOLLOW UP; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTPATIENT CARE; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRESCRIPTION; PROSPECTIVE STUDY; PSYCHOPHARMACOTHERAPY; RELAPSE; RISK ASSESSMENT; SCHIZOPHRENIA; TREATMENT PLANNING;

EID: 84866505409     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S26253     Document Type: Article

References (39)

1. Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 2002;63(10):892-909.
2. Ascher-Svanum H, Faries DE, Zhu B, Ernst FR, Swartz MS, Swanson JW. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry. 2006;67(3): 453-460.
3. Law MR, Soumerai SB, Ross-Degnan D, Adams AS. A longitudinal study of medication nonadherence and hospitalization risk in schizophrenia. J Clin Psychiatry. 2008;69(1):47-53.
4. Lieberman JA, Stroup TS, McEvoy JP, et al; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia [published correction appears in N Engl J Med. 2010;363(11):1092-1093]. N Engl J Med. 2005;353(12):1209-1223.
5. Mueser KT, McGurk SR. Schizophrenia. Lancet. 2004;363(9426): 2063-2072.
6. Davis JM, Matalon L, Watanabe MD, Blake L, Metalon L. Depot antipsychotic drugs. Place in therapy. Drugs. 1994;47(5):741-773.
7. Patel MX, Taylor M, David AS. Antipsychotic long-acting injections: mind the gap. Br J Psychiatry Suppl. 2009;52:S1-S4.
8. Rosenheck RA, Krystal JH, Lew R, et al; CSP555 Research Group. Long-acting risperidone and oral antipsychotics in unstable schizophrenia. N Engl J Med. 2011;364(9):842-851.
9. Leucht C, Heres S, Kane JM, Kissling W, Davis JM, Leucht S. Oral versus depot antipsychotic drugs for schizophrenia-A critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res. 2011;127(1-3):83-92.
10. Tiihonen J, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry. 2011;168(6): 603-609.
11. West JC, Marcus SC, Wilk J, Countis LM, Regier DA, Olfson M. Use of depot antipsychotic medications for medication nonadherence in schizophrenia. Schizophr Bull. 2008;34(5):995-1001.
12. Heres S, Reichhart T, Hamann J, Mendel R, Leucht S, Kissling W. Psychiatrists' attitude to antipsychotic depot treatment in patients with first-episode schizophrenia. Eur Psychiatry. 2011;26(5):297-301.
13. Heres S, Hamann J, Kissling W, Leucht S. Attitudes of psychiatrists toward antipsychotic depot medication. J Clin Psychiatry. 2006;67(12):1948-1953.
14. Ciudad A, San L, Bernardo M, et al. Relapse and therapeutic interventions in a 1-year observational cohort study of nonadherent outpatients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. In press. 2011.
15. Amador XF, Flaum M, Andreasen NC, et al. Awareness of illness in schizophrenia and schizoaffective and mood disorders. Arch Gen Psychiatry. 1994;51(10):826-836.
16. Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med. 1983;13(1):177-183.
17. Cannon-Spoor HE, Potkin SG, Wyatt RJ. Measurement of premorbid adjustment in chronic schizophrenia. Schizophr Bull. 1982;8(3): 470-484.
18. Clinical global impression. In: Guy W, editor. ECDEU Assessment Manual for Psychopharmacology, Revised. Rockville MD: National Institute for Mental Health; 1976:217-222.
19. Oliva-Moreno J, López-Bastida J, Osuna-Guerrero R, Montejo-González AL, Duque-González B. The costs of schizophrenia in Spain. Eur J Health Econ. 2006;7(3):182-188.
20. Colleges of Pharmacists Spanish Council. Official medicines catalog. https://botplusweb.portalfarma.com/. Accessed December 15, 2010.
21. Vázquez-Polo FJ, Negrín M, Cabasés JM, Sánchez E, Haro JM, Salvador-Carulla L. An analysis of costs of treating schizophrenia in Spain: a hierarchical Bayesian approach. J Ment Health Policy Econ. 2005;8(3):153-165.
22. Oblikue Consulting SL. Oblikue Consulting eSALUD-Healthcare database on costs, 2008. http://oblikue.com/bddcostes. Accessed November 24, 2010.
23. Shi L, Ascher-Svanum H, Zhu B, Faries D, Montgomery W, Marder SR. Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia. Psychiatr Serv. 2007;58(4):482-488.
24. Keith SJ, Kane JM, Turner M, Conley RR, Nasrallah HA. Academic highlights: guidelines for the use of long-acting injectable atypical antipsychotics. J Clin Psychiatry. 2004;65(1):120-131.
25. Kelin K, Brnabic AJ, Newton R, et al. Baseline characteristics and initial treatment decisions for patients with schizophrenia at risk of treatment nonadherence. Patient Prefer Adherence. 2010;4:301-311.
26. Heres S, Hamann J, Mendel R, et al. Identifying the profile of optimal candidates for antipsychotic depot therapy A cluster analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(8):1987-1993.
27. Janssen-Cilag. Risperdal-Consta. Summary of Product Characteristics. http://www.ema.europa.eu/ema/index.jsp?curlhpages/medicines/ human/referrals/Risperdal_Consta/human_referral_000027. jsp&murljmenus/regulations/regulations.jsp. Accessed February 16, 2011.
28. Eerdekens M, Van Hove I, Remmerie B, Mannaert E. Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. Schizophr Res. 2004;70(1):91-100.
29. Taylor D. Psychopharmacology and adverse effects of antipsychotic longacting injections: a review. Br J Psychiatry. 2009;195(52):S13-S19.
30. Taylor D, Mir S, Mace S, Whiskey E. Co-prescribing of atypical and typical antipsychotics-prescribing sequence and documented outcome. Psychiatr Bull. 2002;26(5):170-172.
31. Peuskens J, Olivares JM, Pecenak J, et al. Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries. Curr Med Res Opin. 2010;26(3):501-509.
32. Patel MX, De Zoysa N, Bernadt M, David A. Depot and oral antipsychotics: patient preferences and attitudes are not the same thing. J Psychopharmacol. 2009;23(7):789-796.
33. Patel MX, Nikolaou V, David AS. Psychiatrists' attitudes to maintenance medication for patients with schizophrenia. Psychol Med. 2003; 33(1):83-89.
34. Patel MX, David AS. Why aren't depot antipsychotics prescribed more often and what can be done about it? Adv Psychiatr Treat. 2005; 11(3):203-211.
35. Caroli F, Raymondet P, Izard I, Plas J, Gall B, Delgado A. Opinions of French patients with schizophrenia regarding injectable medication. Patient Prefer Adherence. 2011;5:165-171.
36. Waddell L, Taylor M. Attitudes of patients and mental health staff to antipsychotic long-acting injections: systematic review. Br J Psychiatry Suppl. 2009;52:S43-S50.
37. Burns T. Knowledge about antipsychotic long-acting injections: bridging that gap. Br J Psychiatry Suppl. 2009;52:S5-S6.
38. Olivares JM, Rodriguez-Martinez A, Buron JA, Alonso-Escolano D, Rodriguez-Morales A. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia: a 12-and 24-month follow-up from the e-STAR database in Spain. Appl Health Econ Health Policy. 2008;6(1):41-53.
39. Ascher-Svanum H, Zhu B, Faries DE, et al. The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC Psychiatry. 2010;10:2.